A Dragon In R&D
As a young man, Zhang Xiaolin dreamed of becoming a top research scientist. But to reach that goal, the native of China's Anhui Province felt he had to leave his homeland. Now, after two decades in the U.S., he's back home again, and he couldn't be happier. Zhang will be heading up drugmaker AstraZeneca's (AZN) Shanghai lab, where he says he expects ``to do real innovative research.'' Adds his boss, James Ward-Lilley, president of AstraZeneca China: ``In 20 years, where do you see new ideas coming from? A significant chunk will be from China.''
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.